AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer
Posted: Wednesday, July 8, 2020
Dual therapy using xentuzumab, an IGF-ligand neutralizing antibody, and abemaciclib, a CDK4/6 inhibitor, showed efficacy with a manageable safety profile in patients with non–small cell lung cancer (NSCLC) who experienced disease progression on chemotherapy and immune checkpoint inhibitors. Patricia LoRusso, DO, of the Yale Cancer Center in New Haven, Connecticut, and colleagues published their study findings during the 2020 American Association for Cancer Research (AAACR) Virtual Annual Meeting II (Abstract CT165).
A total of 25 patients with stage IV NSCLC and measurable disease were treated in this phase Ib study. All patients had experienced disease progression after being treated with platinum-based chemotherapy and immunotherapy or one or two chemotherapies, or they were ineligible for standard second-line chemotherapy. Participants were administered 1,000 mg of xentuzumab weekly plus 150 mg of abemaciclib every 12 hours until either disease progression or intolerability.
At the time of analysis, the median treatment exposure was 1.6 months, and four patients remained on the therapy. A total of 19 patients were evaluated for response, including 1 whose best overall response was a partial response (defined as 65% shrinkage of the target lesion), 9 patients with stable disease, and 9 with disease progression. Three patients maintained stable disease for over 24 weeks. The median progression-free survival was 2.1 months among all patients.
Adverse events occurred in all study participants, with 23 experiencing treatment-related adverse events. The most common treatment side effects of any grade included diarrhea (15 patients), nausea (10 patients), and a decreased platelet count (8 patients). Grade 3 or higher adverse events seen in this population included thrombocytopenia (4 patients) and neutropenia (3 patients). No patients experienced hyperglycemia or an increase in blood glucose. Serious adverse events occurred in 13 patients, with 2 dying as a result of disease progression and respiratory failure.
Disclosures: For a full list of authors’ disclosures, visit abstractsonline.com.
